Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Influence of Stereochemistry on the Bioactivation and Glucuronidation of 4-Ipomeanol.

Teitelbaum AM, McDonald MG, Kowalski JP, Parkinson OT, Scian M, Whittington D, Roellecke K, Hanenberg H, Wiek C, Rettie AE.

J Pharmacol Exp Ther. 2018 Nov 8. pii: jpet.118.249771. doi: 10.1124/jpet.118.249771. [Epub ahead of print]

2.

Preface to Special Issue on 'Cytochrome P450 Variation in Pharmacogenomics'.

Rettie AE, Liggett SB.

J Pers Med. 2018 Jul 4;8(3). pii: E23. doi: 10.3390/jpm8030023. No abstract available.

3.

Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach.

Johnson EJ, González-Peréz V, Tian DD, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 Jul;46(7):1046-1052. doi: 10.1124/dmd.118.081273. Epub 2018 May 7.

PMID:
29735752
4.

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Daly AK, Rettie AE, Fowler DM, Miners JO.

J Pers Med. 2017 Dec 28;8(1). pii: E1. doi: 10.3390/jpm8010001. Review.

5.

Dietary Vitamin K and Association with Hepatic Vitamin K Status in a Yup'ik Study Population from Southwestern Alaska.

Au NT, Ryman T, Rettie AE, Hopkins SE, Boyer BB, Black J, Philip J, Yracheta J, Fohner AE, Reyes M, Thornton TA, Austin MA, Thummel KE.

Mol Nutr Food Res. 2018 Feb;62(3). doi: 10.1002/mnfr.201700746. Epub 2017 Dec 29.

PMID:
29094808
6.

Expression and Functional Characterization of Breast Cancer-Associated Cytochrome P450 4Z1 in Saccharomyces cerevisiae.

McDonald MG, Ray S, Amorosi CJ, Sitko KA, Kowalski JP, Paco L, Nath A, Gallis B, Totah RA, Dunham MJ, Fowler DM, Rettie AE.

Drug Metab Dispos. 2017 Dec;45(12):1364-1371. doi: 10.1124/dmd.117.078188. Epub 2017 Oct 10.

7.

Genetic and Nongenetic Factors Associated with Protein Abundance of Flavin-Containing Monooxygenase 3 in Human Liver.

Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, Schuetz E, Rettie AE, Leeder JS, Thummel KE, Prasad B.

J Pharmacol Exp Ther. 2017 Nov;363(2):265-274. doi: 10.1124/jpet.117.243113. Epub 2017 Aug 17.

8.

Longitudinal characterisation of function and structure of Bietti crystalline dystrophy: report on a novel homozygous mutation in CYP4V2.

Lockhart CM, Smith TB, Yang P, Naidu M, Rettie AE, Nath A, Weleber R, Kelly EJ.

Br J Ophthalmol. 2018 Feb;102(2):187-194. doi: 10.1136/bjophthalmol-2016-309696. Epub 2017 Jul 11.

PMID:
28698241
9.

Dietary and genetic influences on hemostasis in a Yup'ik Alaska Native population.

Au NT, Reyes M, Boyer BB, Hopkins SE, Black J, O'Brien D, Fohner AE, Yracheta J, Thornton T, Austin MA, Burke W, Thummel KE, Rettie AE.

PLoS One. 2017 Apr 4;12(4):e0173616. doi: 10.1371/journal.pone.0173616. eCollection 2017.

10.

The Crystal Structure of Cytochrome P450 4B1 (CYP4B1) Monooxygenase Complexed with Octane Discloses Several Structural Adaptations for ω-Hydroxylation.

Hsu MH, Baer BR, Rettie AE, Johnson EF.

J Biol Chem. 2017 Mar 31;292(13):5610-5621. doi: 10.1074/jbc.M117.775494. Epub 2017 Feb 6.

11.

Ligand characterization of CYP4B1 isoforms modified for high-level expression in Escherichia coli and HepG2 cells.

Roellecke K, Jäger VD, Gyurov VH, Kowalski JP, Mielke S, Rettie AE, Hanenberg H, Wiek C, Girhard M.

Protein Eng Des Sel. 2017 Mar 1;30(3):205-216. doi: 10.1093/protein/gzw075.

12.

CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.

Flora DR, Rettie AE, Brundage RC, Tracy TS.

J Clin Pharmacol. 2017 Mar;57(3):382-393. doi: 10.1002/jcph.813. Epub 2016 Sep 22.

PMID:
27539372
13.

Association of FMO3 Variants and Trimethylamine N-Oxide Concentration, Disease Progression, and Mortality in CKD Patients.

Robinson-Cohen C, Newitt R, Shen DD, Rettie AE, Kestenbaum BR, Himmelfarb J, Yeung CK.

PLoS One. 2016 Aug 11;11(8):e0161074. doi: 10.1371/journal.pone.0161074. eCollection 2016.

14.

Species Differences in Microsomal Oxidation and Glucuronidation of 4-Ipomeanol: Relationship to Target Organ Toxicity.

Parkinson OT, Teitelbaum AM, Whittington D, Kelly EJ, Rettie AE.

Drug Metab Dispos. 2016 Oct;44(10):1598-602. doi: 10.1124/dmd.116.070003. Epub 2016 Jul 28.

15.

Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.

Towles JK, Clark RN, Wahlin MD, Uttamsingh V, Rettie AE, Jackson KD.

Drug Metab Dispos. 2016 Oct;44(10):1584-97. doi: 10.1124/dmd.116.070839. Epub 2016 Jul 22.

16.

Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.

Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, von Laer D, Scheckenbach K, Wagenmann M, Reinhardt D, Kramm CM, Rettie AE, Wiek C, Hanenberg H.

Gene Ther. 2016 Jul;23(7):615-26. doi: 10.1038/gt.2016.38. Epub 2016 May 19.

PMID:
27092941
17.

Efficient Syntheses of Vitamin K Chain-Shortened Acid Metabolites.

Teitelbaum AM, Scian M, Nelson WL, Rettie AE.

Synthesis (Stuttg). 2015 Apr;47(7):944-948.

18.

Characterization of an Additional Splice Acceptor Site Introduced into CYP4B1 in Hominoidae during Evolution.

Schmidt EM, Wiek C, Parkinson OT, Roellecke K, Freund M, Gombert M, Lottmann N, Steward CA, Kramm CM, Yarov-Yarovoy V, Rettie AE, Hanenberg H.

PLoS One. 2015 Sep 10;10(9):e0137110. doi: 10.1371/journal.pone.0137110. eCollection 2015.

19.

Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, Rettie AE, Schuetz EG, Thummel KE.

Pharmacogenomics J. 2016 Aug;16(4):375-87. doi: 10.1038/tpj.2015.58. Epub 2015 Sep 1.

20.

P450-Based Drug-Drug Interactions of Amiodarone and its Metabolites: Diversity of Inhibitory Mechanisms.

McDonald MG, Au NT, Rettie AE.

Drug Metab Dispos. 2015 Nov;43(11):1661-9. doi: 10.1124/dmd.115.065623. Epub 2015 Aug 21.

21.

Genome-wide association study of warfarin maintenance dose in a Brazilian sample.

Parra EJ, Botton MR, Perini JA, Krithika S, Bourgeois S, Johnson TA, Tsunoda T, Pirmohamed M, Wadelius M, Limdi NA, Cavallari LH, Burmester JK, Rettie AE, Klein TE, Johnson JA, Hutz MH, Suarez-Kurtz G.

Pharmacogenomics. 2015;16(11):1253-63. doi: 10.2217/PGS.15.73. Epub 2015 Aug 12.

22.

Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Johnson AL, Edson KZ, Totah RA, Rettie AE.

Adv Pharmacol. 2015;74:223-62. doi: 10.1016/bs.apha.2015.05.002. Epub 2015 Jun 27. Review.

23.

Variation in genes controlling warfarin disposition and response in American Indian and Alaska Native people: CYP2C9, VKORC1, CYP4F2, CYP4F11, GGCX.

Fohner AE, Robinson R, Yracheta J, Dillard DA, Schilling B, Khan B, Hopkins S, Boyer B, Black J, Wiener H, Tiwari HK, Gordon A, Nickerson D, Tsai JM, Farin FM, Thornton TA, Rettie AE, Thummel KE.

Pharmacogenet Genomics. 2015 Jul;25(7):343-353. doi: 10.1097/FPC.0000000000000143.

24.

Human valacyclovir hydrolase/biphenyl hydrolase-like protein is a highly efficient homocysteine thiolactonase.

Marsillach J, Suzuki SM, Richter RJ, McDonald MG, Rademacher PM, MacCoss MJ, Hsieh EJ, Rettie AE, Furlong CE.

PLoS One. 2014 Oct 15;9(10):e110054. doi: 10.1371/journal.pone.0110054. eCollection 2014.

25.

Identification of amino acid determinants in CYP4B1 for optimal catalytic processing of 4-ipomeanol.

Wiek C, Schmidt EM, Roellecke K, Freund M, Nakano M, Kelly EJ, Kaisers W, Yarov-Yarovoy V, Kramm CM, Rettie AE, Hanenberg H.

Biochem J. 2015 Jan 1;465(1):103-14. doi: 10.1042/BJ20140813.

26.

Generation and characterization of a murine model of Bietti crystalline dystrophy.

Lockhart CM, Nakano M, Rettie AE, Kelly EJ.

Invest Ophthalmol Vis Sci. 2014 Aug 12;55(9):5572-81. doi: 10.1167/iovs.13-13717.

27.

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing.

Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, Klein TE, Callaghan JT; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2014 Nov;96(5):542-8. doi: 10.1038/clpt.2014.159. Epub 2014 Aug 6.

28.

Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Nakano M, Lockhart CM, Kelly EJ, Rettie AE.

Drug Metab Rev. 2014 Aug;46(3):247-60. doi: 10.3109/03602532.2014.921190. Epub 2014 May 26. Review.

29.

Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.

Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL.

Clin Pharmacol Ther. 2014 Jun;95(6):636-43. doi: 10.1038/clpt.2014.26. Epub 2014 Feb 6.

30.

Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents.

Pandey RN, Wang TS, Tadjuidje E, McDonald MG, Rettie AE, Hegde RS.

PLoS One. 2013 Dec 18;8(12):e84582. doi: 10.1371/journal.pone.0084582. eCollection 2013.

31.

A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites.

Haque JA, McDonald MG, Kulman JD, Rettie AE.

Blood. 2014 Jan 23;123(4):582-9. doi: 10.1182/blood-2013-05-505123. Epub 2013 Dec 2.

32.

Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.

Hardy KD, Wahlin MD, Papageorgiou I, Unadkat JD, Rettie AE, Nelson SD.

Drug Metab Dispos. 2014 Jan;42(1):162-71. doi: 10.1124/dmd.113.054817. Epub 2013 Nov 4.

33.

Cytochrome P450-dependent catabolism of vitamin K: ω-hydroxylation catalyzed by human CYP4F2 and CYP4F11.

Edson KZ, Prasad B, Unadkat JD, Suhara Y, Okano T, Guengerich FP, Rettie AE.

Biochemistry. 2013 Nov 19;52(46):8276-85. doi: 10.1021/bi401208m. Epub 2013 Nov 7.

34.

Association of CYP2C9*2 with bosentan-induced liver injury.

Markova SM, De Marco T, Bendjilali N, Kobashigawa EA, Mefford J, Sodhi J, Le H, Zhang C, Halladay J, Rettie AE, Khojasteh C, McGlothlin D, Wu AH, Hsueh WC, Witte JS, Schwartz JB, Kroetz DL.

Clin Pharmacol Ther. 2013 Dec;94(6):678-86. doi: 10.1038/clpt.2013.143. Epub 2013 Jul 17.

35.

Generation and characterization of a Cyp4b1 null mouse and the role of CYP4B1 in the activation and toxicity of Ipomeanol.

Parkinson OT, Liggitt HD, Rettie AE, Kelly EJ.

Toxicol Sci. 2013 Aug;134(2):243-50. doi: 10.1093/toxsci/kft123. Epub 2013 Jun 7.

37.

ω-Hydroxylation of phylloquinone by CYP4F2 is not increased by α-tocopherol.

Farley SM, Leonard SW, Taylor AW, Birringer M, Edson KZ, Rettie AE, Traber MG.

Mol Nutr Food Res. 2013 Oct;57(10):1785-93. doi: 10.1002/mnfr.201200797. Epub 2013 May 3.

38.

Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis.

Danese E, Montagnana M, Johnson JA, Rettie AE, Zambon CF, Lubitz SA, Suarez-Kurtz G, Cavallari LH, Zhao L, Huang M, Nakamura Y, Mushiroda T, Kringen MK, Borgiani P, Ciccacci C, Au NT, Langaee T, Siguret V, Loriot MA, Sagreiya H, Altman RB, Shahin MH, Scott SA, Khalifa SI, Chowbay B, Suriapranata IM, Teichert M, Stricker BH, Taljaard M, Botton MR, Zhang JE, Pirmohamed M, Zhang X, Carlquist JF, Horne BD, Lee MT, Pengo V, Guidi GC, Minuz P, Fava C.

Clin Pharmacol Ther. 2012 Dec;92(6):746-56. doi: 10.1038/clpt.2012.184. Epub 2012 Nov 7. Review.

39.

Identifying safer anti-wear triaryl phosphate additives for jet engine lubricants.

Baker PE, Cole TB, Cartwright M, Suzuki SM, Thummel KE, Lin YS, Co AL, Rettie AE, Kim JH, Furlong CE.

Chem Biol Interact. 2013 Mar 25;203(1):257-64. doi: 10.1016/j.cbi.2012.10.005. Epub 2012 Oct 22.

40.
41.

Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites.

McDonald MG, Au NT, Wittkowsky AK, Rettie AE.

Clin Pharmacol Ther. 2012 Apr;91(4):709-17. doi: 10.1038/clpt.2011.283. Epub 2012 Mar 7.

42.

Bioactivation of 4-Ipomeanol by a CYP4B enzyme in bovine lung and inhibition by HET0016.

Parkinson OT, Kelly EJ, Bezabih E, Whittington D, Rettie AE.

J Vet Pharmacol Ther. 2012 Aug;35(4):402-5. doi: 10.1111/j.1365-2885.2011.01339.x. Epub 2011 Sep 15. No abstract available.

43.

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue.

Innocenti F, Cooper GM, Stanaway IB, Gamazon ER, Smith JD, Mirkov S, Ramirez J, Liu W, Lin YS, Moloney C, Aldred SF, Trinklein ND, Schuetz E, Nickerson DA, Thummel KE, Rieder MJ, Rettie AE, Ratain MJ, Cox NJ, Brown CD.

PLoS Genet. 2011 May;7(5):e1002078. doi: 10.1371/journal.pgen.1002078. Epub 2011 May 26.

44.

Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.

Kelly EJ, Nakano M, Rohatgi P, Yarov-Yarovoy V, Rettie AE.

Mol Interv. 2011 Apr;11(2):124-32. doi: 10.1124/mi.11.2.10. Review.

45.

Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.

Baillie TA, Rettie AE.

Drug Metab Pharmacokinet. 2011;26(1):15-29. Epub 2010 Oct 22. Review.

46.

Intramolecular heme ligation of the cytochrome P450 2C9 R108H mutant demonstrates pronounced conformational flexibility of the B-C loop region: implications for substrate binding.

Roberts AG, Cheesman MJ, Primak A, Bowman MK, Atkins WM, Rettie AE.

Biochemistry. 2010 Oct 12;49(40):8700-8. doi: 10.1021/bi100911q. Epub 2010 Sep 21.

47.

Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs.

Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, Becker C, Palme MP, Paliard X, Bowersox S, Dennis DM, Druzgala P.

Br J Pharmacol. 2009 Nov;158(6):1536-47. doi: 10.1111/j.1476-5381.2009.00420.x. Epub 2009 Oct 20.

48.

Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase.

Nakano M, Kelly EJ, Rettie AE.

Drug Metab Dispos. 2009 Nov;37(11):2119-22. doi: 10.1124/dmd.109.028530. Epub 2009 Aug 6.

49.

CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant.

McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE.

Mol Pharmacol. 2009 Jun;75(6):1337-46. doi: 10.1124/mol.109.054833. Epub 2009 Mar 18.

50.

CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry.

Mosher CM, Tai G, Rettie AE.

J Pharmacol Exp Ther. 2009 Jun;329(3):938-44. doi: 10.1124/jpet.109.150706. Epub 2009 Mar 3.

Supplemental Content

Loading ...
Support Center